Wuhan Bio-Raid Biotechnology Co, Ltd. China   Report issue

Government Phase 1
Founded: Wuhan China (2014)

Organization Overview

First Clinical Trial
2019
NCT04007978
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Wuhan Bio-Raid Biotechnology Co., Ltd. | Wuhan Bio-Raid Biotechnology Co, Ltd. China

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Immunoblastic Lymphadenopathy (Phase 1)

Leukemia (Phase 1)

Leukemia-Lymphoma, Adult T-Cell (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Lymphoma (Phase 1)

Lymphoma, Large-Cell, Anaplastic (Phase 1)

Lymphoma, T-Cell (Phase 1)

Lymphoma, T-Cell, Peripheral (Phase 1)

Neoplasms (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 3